These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37771317)

  • 1. Vaccination therapy for inflammatory bowel disease.
    Liu Y; Liao F
    Hum Vaccin Immunother; 2023 Aug; 19(2):2259418. PubMed ID: 37771317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research progress of Ustekinumab in the treatment of inflammatory bowel disease.
    Zhang W; Zhong G; Ren X; Li M
    Front Immunol; 2024; 15():1322054. PubMed ID: 38455044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
    Asscher VER; Biemans VBC; Pierik MJ; Dijkstra G; Löwenberg M; van der Marel S; de Boer NKH; Bodelier AGL; Jansen JM; West RL; Haans JJL; van Dop WA; Weersma RK; Hoentjen F; Maljaars PWJ;
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1366-1376. PubMed ID: 32901983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
    Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
    Dai C; Dong ZY; Wang YN; Huang YH; Jiang M
    Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.
    Benchimol EI; Tse F; Carroll MW; deBruyn JC; McNeil SA; Pham-Huy A; Seow CH; Barrett LL; Bessissow T; Carman N; Melmed GY; Vanderkooi OG; Marshall JK; Jones JL
    Gastroenterology; 2021 Aug; 161(2):669-680.e0. PubMed ID: 33617891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
    Verstockt B; Deleenheer B; Van Assche G; Vermeire S; Ferrante M
    Expert Opin Drug Saf; 2017 Jul; 16(7):809-821. PubMed ID: 28573876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.
    Conforti C; Dianzani C; Zalaudek I; Cicala M; Persichetti P; Giuffrida R; Morariu SH; Neagu N
    J Dermatolog Treat; 2022 May; 33(3):1279-1286. PubMed ID: 33074781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud D; Vermeire S; Verstockt B
    Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Radhakrishnan ST; Alexander JL; Mullish BH; Gallagher KI; Powell N; Hicks LC; Hart AL; Li JV; Marchesi JR; Williams HRT
    Aliment Pharmacol Ther; 2022 Jan; 55(1):26-48. PubMed ID: 34751954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review.
    Yerushalmy-Feler A; Brauner C; Cohen S
    Paediatr Drugs; 2023 Sep; 25(5):489-498. PubMed ID: 37318737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.